Pasar al contenido principal

ESTUDIO DE NUEVOS GENES DEPENDIENTES DE LA RUTA ERK5 EN PATOLOGIA SARCOMATOIDE: IMPLICACIONES EN BIOLOGIA TUMORAL Y TERAPIA.

PID2021-122222OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents

  • Díaz de Greñu, Borja
  • Fernández-Aroca, Diego M.
  • Organero, Juan A.
  • Durán, Gema
  • Jalón, Félix A.
  • Sánchez-Prieto, Ricardo
  • Ruiz-Hidalgo, María J.
  • Rodríguez, Ana María
  • Santos, Lucía
  • Albasanz, José L.
  • Manzano, Blanca R.
In the treatment of hormone-dependent cancers, aromatase inhibitors (AI) are receiving increased attention due to some undesirable effects such as the risk of endometrial cancer and thromboembolism of SERMs (selective estrogen receptor modulators). Letrozole is the most active AI with 99% aromatase inhibition. Unfortunately, this compound also exhibits some adverse effects such as hot flashes and fibromyalgias. Therefore, there is an urgent need to explore new types of AIs that retain the same—or even increased—antitumor ability. Inspired by the letrozole structure, a set of new derivatives has been synthesized that include a ferrocenyl moiety and different heterocycles. The derivative that contains a benzimidazole ring, namely compound 6, exhibits a higher aromatase inhibitory activity than letrozole and it also shows potent cytostatic behavior when compared to other well-established aromatase inhibitors, as demonstrated by dose–response, cell cycle, apoptosis and time course experiments. Furthermore, 6 promotes the inhibition of cell growth in both an aromatase-dependent and -independent fashion, as indicated by the study of A549 and MCF7 cell lines. Molecular docking and molecular dynamics calculations on the interaction of 6 or letrozole with the aromatase binding site revealed that the ferrocene moiety increases the van der Waals and hydrophobic interactions, thus resulting in an increase in binding affinity. Furthermore, the iron atom of the ferrocene fragment can form a metal-acceptor interaction with a propionate fragment, and this results in a stronger coupling with the heme group—a possibility that is consistent with the strong aromatase inhibition of 6., This work was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU), Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER), Grant PID2021-127187OB-C21 to BRM, MCIN/AEI/10.13039/501100011033, Grant PID2021-122222OB-I00 “ERDF A way of making Europe” to RSP, Junta de Comunidades de Castilla-La Mancha-FEDER (JCCM) (Grants SBPLY/19/180501/000260 to BRM and SBPLY/19/180501/000251 to JLA), and UCLM-FEDER (Grants 2019-GRIN-27183, 2019-GRIN-27209, 2020-GRIN-29093 to FAJ and 2021-GRIN-31118 to JLA). Funds from Fundación Leticia Castillejo Castillo (2021-AYUDA-32401) to RSP and MJRH are also acknowledged. RSP and MJRH’s Research Institute and the work carried out in their laboratory, received partial support from the European Community through the FEDER. CG wants to acknowledge his fellowship to both the European Social Fund and Plan Propio of I+D+I of UCLM (2022-PRED-20649). GD thanks the Junta de Comunidades de Castilla la Mancha and EU for financial support through the European Regional Development Fund (project SBPLY/19/180501/000191)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

P38 MAPK and Radiotherapy: Foes or Friends?

  • García-Flores, Natalia
  • Jiménez-Suárez, Jaime
  • Garnés-García, Cristina
  • Fernández-Aroca, Diego M.
  • Sabater, Sebastiá
  • Andrés, I.
  • Fernández-Aramburo, Antonio
  • Ruiz-Hidalgo, María J.
  • Belandia, Borja
  • Sánchez-Prieto, Ricardo
  • Cimas, Francisco J.
Over the last 30 years, the study of the cellular response to ionizing radiation (IR) has increased exponentially. Among the various signaling pathways affected by IR, p38 MAPK has been shown to be activated both in vitro and in vivo, with involvement in key processes triggered by IR-mediated genotoxic insult, such as the cell cycle, apoptosis or senescence. However, we do not yet have a definitive clue about the role of p38 MAPK in terms of radioresistance/sensitivity and its potential use to improve current radiotherapy. In this review, we summarize the current knowledge on this family of MAPKs in response to IR as well as in different aspects related to radiotherapy, such as their role in the control of REDOX, fibrosis, and in the radiosensitizing effect of several compounds., This work has been supported by grant PID2021-122222OB-I00 funded by MCIN/AEI /10.13039/501100011033/ and by FEDER A way to make Europe. F.J. Cimas is funded by contracts for post-doctoral researchers for scientific excellence in the development of the Plan Propio I+D+i, co-financed by the European Social Fund Plus (ESF+). N. García-Flores is funded by the “Investigo Programme” for hiring young job seekers to carry out research and innovation initiatives within the framework of the Recovery, Transformation and Resilience Plan, Next Generation EU, which is financed by the European Union, called by Order 190/2021 of the Regional Ministry of Economy, Business and Employment of the Regional Government of Castilla-La Mancha on 22 December. J. Jiménez-Suárez is funded by the “Contrato predoctoral para la formación de personal investigador” en el marco del plan propio de I+D+I UCLM 2020-PREDUCLM-15144. co-financed by the European Social Fund Plus (ESF+)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Osmotic stress influences microtubule drug response via WNK1 kinase signaling

  • Monfort-Vengut, Ana
  • Sanz-Gómez, Natalia
  • Ballesteros-Sánchez, Sandra
  • Ortigosa, Beatriz
  • Cambón, Aitana
  • Ramos, María
  • Montes-San Lorenzo, Ángela
  • Escribano-Cebrián, María
  • Rosa-Rosa, Juan M.
  • Martínez-López, Joaquín
  • Sánchez-Prieto, Ricardo
  • Sotillo, Rocío
  • Cárcer, Guillermo de
Ion homeostasis is critical for numerous cellular processes, and disturbances in ionic balance underlie diverse pathological conditions, including cancer progression. Targeting ion homeostasis is even considered as a strategy to treat cancer. However, very little is known about how ion homeostasis may influence anticancer drug response. In a genome-wide CRISPR-Cas9 resistance drug screen, we identified and validated the master osmostress regulator WNK1 kinase as a modulator of the response to the mitotic inhibitor rigosertib. Osmotic stress and WNK1 inactivation lead to an altered response not only to rigosertib treatment but also to other microtubule-related drugs, minimizing the prototypical mitotic arrest produced by these compounds. This effect is due to an alteration in microtubule stability and polymerization dynamics, likely maintained by fluctuations in intracellular molecular crowding upon WNK1 inactivation. This promotes resistance to microtubule depolymerizing compounds, and increased sensitivity to microtubule stabilizing drugs. In summary, our data proposes WNK1 osmoregulation activity as an important modulator for microtubule-associated chemotherapy response., This study has been financed by the following grants: From the Ministerio de Ciencia, Innovación, Agencia Estatal de Investigación MCIN/AEI/FEDER UE (doi:10.13039/501100011033): RTI2018–095496-B-I00 and PID2021–125705OB-I00 (GdC); PID2021–122222OB-I00 (RSP); Juan de la Cierva Postdoctoral program FJC2020–044620-I (NSG). From the Spanish Association Against Cancer (AECC) Scientific Foundation: LABAE16017DECA (GdC) and POSTD234371SANZ (NSG). From the Spanish National Research Council (CSIC) with grants 201820I114, 2021-AEP035, 2022–20I018 (GdC), JAEINT_22_01172 (SBS), and JAEINT_24_01201 (MEC). From the UCLM with grant 2022-GRIN-34150 (RSP). EMBO Scientific Exchange Grant (SEG-9883) to AMV, in RS laboratory., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The CDK12-BRCA1 signaling axis mediates dinaciclib-associated radiosensitivity through p53-mediated cellular senescence

  • Flores, Natalia García
  • Fernández-Aroca, Diego M.
  • Garnés-García, Cristina
  • Domínguez-Calvo, Andrés
  • Jiménez-Suárez, Jaime
  • Sabater, Sebastià
  • Fernández-Aroca, Pablo
  • Andrés, Ignacio
  • Cimas, Francisco J.
  • de Cárcer, Guillermo
  • Belandia, Borja
  • Palmero, Ignacio
  • Huertas, Pablo
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
Pan-cyclin-dependent-kinase (CDK) inhibitors are a new class of targeted therapies that can act on multiple CDKs, with dinaciclib being one of the most promising compounds. Although used as a monotherapy, an interesting approach could be to combine it with radiotherapy. Here, we show that dinaciclib increases radiosensitivity in some experimental models of lung and colon cancer (A549 or HCT 116) but not in others (H1299 or HT-29). Dinaciclib did not alter serine-protein kinase ATM signalling or cell cycle profiling after ionising-radiation exposure, which have been described for other CDK inhibitors. Interestingly, in terms of apoptosis, although the combination renders a clear increase, no potentiation of the ionising-radiation-induced apoptosis was observed. Mechanistically, inhibition of CDK12 by dinaciclib diminishes BRCA1 expression, which decreases homologous recombination (HR) and probably promotes the nonhomologous end joining repair process (NHEJ), which ultimately promotes the induction of ionising-radiation-associated cellular senescence in a TP53-dependent manner, explaining the lack of effect observed in some experimental models. In conclusion, our report proposes a molecular mechanism, based on the signalling axis CDK12-BRCA1, involved in this newly identified therapeutic effect of dinaciclib, although other players implicated in HR should not be discarded. In addition, our data provide a rationale for more selective and personalised chemo/radiotherapy treatment according to the genetic background of the tumour., We appreciate the technical assistance of SIB at IB, core facilities of IIB and the staff from the Radiotherapy Unit at the General Universitary Hospital of Albacete This work has been supported by grant PID2021-122222OB-I00 and PID2021-122600OB-I00 funded by MCIN/AEI/10.13039/501100011033/ and by Europena Regional Development Fund (FEDER) A way to make Europe and grant to RS-P and IP. S2022/BMD-7393 funded by Regional Government of Madrid to IP. PH lab is funded by grant PID2022-136791NB-I00 from MICIU/AEI/10.13039/501100011033/FEDER/UE. RS-P is also funded by UCLM with grant 2022-GRIN-34150 and by Agencia de Investigación e Innovación, Junta de Comunidades de Castilla-La Mancha grant SBPLY/23/180225/000007. FJC is funded by contracts for postdoctoral researchers for scientific excellence in the development of the Plan Propio I + D + i, co-financed by the European Social Fund Plus (ESF+). NGF is funded by ‘Investigo Programme’, for hiring young job seekers to carry out research and innovation initiatives, within the framework of the Recovery, Transformation and Resilience Plan – financed by the European Union – Next Generation EU, called by Order 190/2021, of 22 December, of the Regional Ministry of Economy, Business and Employment of the Regional Government of Castilla-La Mancha. JJ-S is funded by ‘Contrato predoctoral para la formación de personal investigador en el marco del plan propio de I + D + I UCLM 2020-PREDUCLM-15144’, co-financed by the European Social Fund Plus (ESF+). AD-C is funded with FPU fellowships from the Ministerio de Educación, Formación Profesional y Deportes (Lpb23). We are grateful for the funds contributed by Fundacion Leticia Castillejo and by the participants in the crowdfunding project ‘Irradiando Esperanza’, in particular to: Taller Solidario Árbol De La Vida (Las Pedroñeras), Asociación Comarcal Contra El Cáncer De Motilla Del Palancar, asociación Jareña Contra el Cancer Junta local contra el cáncer de Casimarro, and ACEPAIN., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

VCAN is essential for ERK5-driven tumorigenesis in soft tissue sarcoma

  • Jiménez-Suárez, Jaime
  • Cimas, Francisco J.
  • Paricio, José Joaquín
  • Belandia, Borja
  • Berrouayel, Yosra
  • Arconada-Luque, Elena
  • Matilla-Almazán, Sofía
  • Soffientini, Cesare
  • Percio, Stefano
  • Redondo-García, Silvia
  • García-Flores, Natalia
  • Garnés-García, Cristina
  • Fernández-Aroca, Pablo
  • Martínez-Gómez, Juan Jesús
  • Fernández-Aramburo, Antonio
  • Nam-Cha, Syong Hyun
  • Rovida, Elisabetta
  • Pandiella, Atanasio
  • Esparís-Ogando, Azucena
  • Pasquali, Sandro
  • Rodríguez Manzaneque, Juan Carlos
  • Peso, Luis del
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
The ERK5 signaling pathway has recently emerged as a critical regulator of soft tissue sarcoma (STS) biology, contributing to tumor initiation, progression, and maintenance. In this study, we identify VCAN, a chondroitin sulfate proteoglycan, as a novel transcriptional target of ERK5 and a central mediator of ERK5-related oncogenesis. Through a combination of genetic (silencing, overexpression) and pharmacological approaches, applied in both a chemically induced murine sarcoma model and several human STS cell lines, we demonstrate that ERK5 positively regulates VCAN expression. Functionally, VCAN silencing (by shRNAs) recapitulates the phenotypes of ERK5 silencing, including impaired migration, adhesion, proliferation, and tumorigenesis. Conversely, VCAN overexpression rescues these effects, confirming its essential role in ERK5-mediated oncogenesis. Furthermore, transcriptomic profiling reveals that VCAN accounts for a substantial portion of ERK5-regulated gene expression program. Analyses of human STS patient samples reveal significantly elevated mRNA levels of both VCAN and ERK5 compared to normal tissues. Notably, a strong correlation between VCAN and ERK5 expression, both at mRNA and protein levels, emerged in biopsies from leiomyosarcomas and undifferentiated pleomorphic sarcomas. Together, these findings uncover VCAN as a key effector in ERK5-driven tumorigenesis and highlight the ERK5/VCAN signaling axis as a promising therapeutic target in soft tissue sarcomas., Agencia Estatal de Investigación, PID2021-122222OB-I00, PID2019-104416RB-I00, PID2020-115605RB-I00 Junta de comunidades de Castilla La Mancha, SBPLY/23/180225/000007. Instituto de Salud Carlos III, https://ror.org/00ca2c886, PI19/00840 Universidad de Castilla La Mancha, 2022-GRIN-34150, No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Specific transcriptional signature dataset of extracellular signal-regulated kinase 5 in leiomyosarcoma derived cell lines

  • Jiménez-Suárez, Jaime
  • Garnés-García, Cristina
  • Fernández-Aroca, Pablo
  • Aparicio-Canada, Juan
  • Belandia, Borja
  • Ruiz-Hidalgo, María J.
  • Sánchez-Prieto, Ricardo
  • Cimas, Francisco J.
Soft-tissue sarcomas, particularly leiomyosarcomas, are aggressive tumors characterized by limited therapeutic options due to an insufficient understanding of their molecular drivers. To identify novel therapeutic targets, we investigated the role of Extracellular signal-regulated kinase-5 (ERK5), a critical signaling protein in soft-tissue sarcoma biology. The primary objective was to define the transcriptomic profile specifically associated with ERK5, enhancing the understanding of molecular mechanisms underlying leiomyosarcoma., This work has been supported by grant PID2021-122222OB-I00 founded by MCIN/AEI/https://doi.org/10.13039/501100011033/ and by European Regional Development Fund (FEDER) A way to make Europe. RSP and MJR are also funded by UCLM with grant 2025-GRIN-38349 and by Agencia de Investigación e Innovación, Junta de Comunidades de Castilla-La Mancha grant SBPLY/23/180225/000007. JJ-S is funded by ‘Contrato predoctoral para la formación de personal investigador en el marco del plan propio de I + D + I UCLM 2020-PREDUCLM-15144’, co-financed by the European Social Fund Plus (ESF+). FJC was funded by contratos de investigadores postdoctorales para la excelencia científica en el desarrollo del Plan Propio de I + D + i, cofinanciada por el Fondo Social Europeo Plus (FSE+). PF-A S is supported by AECC (contract PRDAB258372FERN). We are grateful for the funds provided by Fundación Leticia Castillejo, Taller Solidario Árbol De La Vida (Las Pedroñeras), Asociación Comarcal Contra El Cáncer De Motilla Del Palancar, and Asociación Jareña Contra el Cáncer., Peer reviewed